This is a prospective randomized double blind trial of patients undergoing selective laser trabeculoplasty for primary open angle glaucoma and ocular hypertension. Enrolled patients are randomized to receive one drop of brimonidine 0.1% in one eye and one drop of apraclonidine 0.5% in the fellow eye. The trabecular meshwork in both eyes of each enrolled patient is treated 360 degrees at the same sitting. Intraocular pressure is measured in each eye one hour before applying the study medications and at one hour and one week after laser surgery.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
male or female, at least 18 years of age
Open Angle Glaucoma with inadequate intraocular pressure (IOP) control or evidence of progression (based on optic nerve head appearance and/or visual field changes) despite current medical therapy
Ocular Hypertension requiring lowering of IOP
ability to understand and provide informed consent to participate in this study and willingness to follow study instructions and likely to complete all required visits
You may not be if
inability to understand and provide informed consent to participate in this study
inability/unwillingness to follow study instructions and complete all required visits
Documented allergy to either brimonidine or iopidine
Angle Closure Glaucoma
Congenital/Juvenile Glaucoma
Neovascular Glaucoma
Active uveitis
Clareo Health | Comparison of the Alpha-2 Agonists for Prevention of Intraocular Pressure Elevation After Selective Laser Trabeculoplasty